Dynamics of resistance development to imatinib under increasing selection pressure: A combination of mathematical models and in vitro data

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Werner, Benjamin ^a   Lutz, David ^b   Brümmendorf, Tim H ^c   Traulsen, Arne ^a   Balabanov, Stefan ^b  

^a MAX PLANCK INSTITUTE FOR EVOLUTIONARY BIOLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PRIMER DNA; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL CLONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; DYNAMICS; IC 50; IN VITRO STUDY; MATHEMATICAL MODEL; MUTATION RATE; PHENOTYPIC VARIATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; CHRONIC MYELOID LEUKEMIA; DRUG RESISTANCE; HUMAN; NUCLEOTIDE SEQUENCE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES;

EID: 84055207498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028955     Document Type: Article

References (53)

1. Mahon FX, Ra D, Guilhot J, Guilhot F, Huguet F, et al. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (stim) trial. Lancet Oncol pp. 1029-1035.
2. Rowley JD, (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine uorescence and giemsa staining. Nature 243: 290-293.
3. Deininger M, Goldman JM, Melo JV, (2000) The molecular biology of chronic myeloid leukemia. Blood 96: 3343-3356.
4. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine 355: 2408-2417.
5. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, et al. (2005) Characterization of amn107, a selective inhibitor of native and mutant bcr-abl. Cancer Cell 7: 129-141.
6. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel abl kinase inhibitor. Science 305: 399-401.
7. Cortes J, Kantarjian H, Brümmendorf T, Kim D, Turkina A, et al. (2011) Safety and efficacy of bosutinib (ski-606) in chronic phase philadelphia chromosome-positive cml patients with resistance or intolerance to imatinib. Blood 355594.
8. Lenaerts T, Pacheco JM, Traulsen A, Dingli D, (2010) Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica 95: 900-907.
9. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, et al. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259.
10. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, et al. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 326: 2260-2270.
11. O'Hare T, Eide CA, Deininger MW, (2007) Bcr-abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242-2249.
12. Bixby D, Talpaz M, (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology American Society of Hematology Education Program Book pp. 461-476.
13. Hochhaus A, La Rosée P, Müller MC, Ernst T, Cross NC, (2011) Impact of bcr-abl mutations on patients with chronic myeloid leukemia. Cell Cycle 10: 250-260.
14. Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA, et al. (2005) Kinase-addiction and bi-phasic sensitivity-resistance of bcr-abl- and raf-1-expressing cells to imatinib and geldanamycin. Cancer Biol Ther 4: 484-490.
15. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, et al. (2009) Ap24534, a pan-bcr-abl inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutationbased resistance. Cancer Cell 16: 401-412.
16. Katouli AA, Komarova NL, (2010) Optimizing combination therapies with existing and future cml drugs. PLoS One 5.
17. Komarova NL, Wodarz D, (2009) Combination therapies against chronic myeloid leukemia: shortterm versus long-term strategies. Cancer Res 69: 4904-4910.
18. Komarova NL, Katouli AA, Wodarz D, (2009) Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PLoS One 4: e4423.
19. Balabanov S, Gontarewicz A, Keller G, Raddrizzani L, Braig M, et al. (2011) Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in bcr-abl-positive cells in vitro. PLoS ONE 6: e19164.
20. Burchert A, Wang Y, CAI D, Bubnoff N, Paschka P, et al. (2005) Compensatory pi3- kinase/akt/mtor activation regulates imatinib resistance development. Leukemia 19: 1774-1782.
21. Patterson MK, (1979) Measurement of growth and viability of cells in culture. Methods Enzymol 58.
22. Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, et al. (2007) Hypusination of eukaryotic initiation factor 5a (eif5a): a novel therapeutic target in bcr-abl-positive leukemias identified by a proteomics approach. Blood 109: 1701-1711.
23. Chou TC, Talalay P, (1981) Generalized equations for the analysis of inhibitions of michaelis-menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115: 207-216.
24. Beillard E, Pallisgaard N, van der Velden VHJ, Bi W, Dee R, et al. (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (rq-pcr)- a europe against cancer program. Leukemia 17: 2474-2486.
25. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, et al. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia- a europe against cancer program. Leukemia 17: 2318-2357.
26. Moran PAP, (1962) The Statistical Processes of Evolutionary Theory. Clarendon Press, Oxford, UK.
27. Nowak MA, (2006) Evolutionary Dynamics. Harvard University Press, Cambridge, MA.
28. Page KM, Nowak MA, (2002) Unifying evolutionary dynamics. J Theor Biol 219: 93-98.
29. Bernoulli J, (1695) Explicationes, annotationes, additiones ad ea, quae in actis sup. anni de curva elastica, isochrona paracentrica, velaria, hinc inde memorata, paratim controversa legundur; ubi de linea mediarum directionum, alliisque novis. Acta Eruditorum 1: 65-80.
30. von Bubnoff N, Peschel C, Duyster J, (2003) Resistance of philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (sti571, glivec): a targeted oncoprotein strikes back. Leukemia 17: 829-838.
31. Blagosklonny MV, (2002) Sti-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. Leukemia 16: 570-572.
32. Drake JW, Charlesworth B, Charlesworth D, Crow JF, (1998) Rates of spontaneous mutation. Genetics 148: 1667-1686.
33. Hicks WM, Kim M, Haber JE, (2010) Increased mutagenesis and unique mutation signature associated with mitotic gene conversion. Science 329: 82-85.
34. Lange T, Park B, Willis SG, Deininger MW, (2005) Bcr-abl kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle 4: 1761-1766.
35. Pene-Dumitrescu T, Smithgall TE, (2010) Expression of a src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 285: 21446-21457.
36. Wu J, Meng F, Kong LY, Peng Z, Ying Y, et al. (2008) Association between imatinib-resistant bcr-abl mutation-negative leukemia and persistent activation of lyn kinase. J Natl Cancer Inst 100: 926-939.
37. Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, et al. (2009) Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol 158: 588-600.
38. Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, et al. (2009) Abnormalities in glucose uptake and metabolism in imatinib-resistant human bcr-abl-positive cells. Clin Cancer Res 15: 3442-3450.
39. Komarova NL, (2011) Mathematical modeling of cyclic treatments of chronic myeloid leukemia. Nath Biosci Eng 8: 289-306.
40. Dingli D, Pacheco JM, (2006) Allometric scaling of the active hematopoietic stem cell pool across mammals. PLoS One 1: e2.
41. Rodriguez-Brenes A, Komarova N, Wodarz D, (2011) Evolutionary dynamics of feedback escape and the development of stem-cell-driven cancers. Proc Natl Acad Sc pp. 18983-18988.
42. Werner B, Dingli D, Lenaerts T, Pacheco JM, Traulsen A, (2011) Dynamics of mutant cells in hierarchical organized tissues. PLoS Comput Biol (in press).
43. Chomel JC, Turhan AG, (2011) Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget pp. 713-727.
44. Peng C, Chen Y, Li D, Li S, (2010) Role of pten in leukemia stem cells. Oncotarget 1: 156-160.
45. Vicente-Dueñas C, Abollo-Jiménez F, Ruiz-Roca L, Alonso-Escudero E, Jiménez R, et al. (2010) The age of the target cell affects b-cell leukaemia malignancy. Aging (Albany NY) pp. 908-913.
46. Lenaerts T, Castagnetti F, Traulsen A, Pacheco JM, Rosti G, et al. (2011) Explaining the in vitro and in vivo differences in leukemia therapy. Cell Cycle 10: 1540-1544.
47. Jiang X, Saw KM, Eaves A, Eaves C, (2007) Instability of bcr-abl gene in primary and cultured chronic myeloid leukemia stem cells. Journal of The National Cancer Institute 99: 680-693.
48. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, et al. (2006) Kinase domain mutants of bcr-abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Molecular and Cellular Biology 26: 6082-6093.
49. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, et al. (2006) Phosphorylation of the atpbinding loop directs oncogenicity of drug-resistant bcr-abl mutants. Proc Natl Acad Sci U S A 103: 19466-19471.
50. Hanfstein B, Müller MC, Kreil S, Ernst T, Schenk T, et al. (2011) Dynamics of mutant bcr-ablpositive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 96: 360-366.
51. Dingli D, Traulsen A, Pacheco JM, (2008) Chronic myeloid leukemia: origin, development, response to therapy, and relapse. Clinical Leukemia 2: 133-139.
52. Andersson DI, (2006) The biological cost of mutational antibiotic resistance: any practical conclusions? Current Opinion in Microbiology 9: 461-465.
53. Andersson DI, Hughes H, (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nature Reviews Microbiology 8: 260-271.